Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 18/20 | 0.68 |
| ▸ | PPARA | Q07869 | 4/20 | 0.66 |
| ▸ | PPARG | P37231 | 2/20 | 0.66 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512645 | 0.92 | PPARD (0.72) | PPARDPPARAPPARG | |
| SCHEMBL5644724 | 0.85 | PPARD (0.64) | PPARDPPARAPPARG | |
| SCHEMBL4839921 | 0.85 | PPARD (0.83) | PPARDPPARAPPARG | |
| SCHEMBL5861715 | 0.83 | PPARD (0.73) | PPARDPPARAPPARG | |
| SCHEMBL4837639 | 0.82 | PPARD (0.61) | PPARDPPARAPPARGPTGDR2 | |
| SCHEMBL4837650 | 0.82 | PPARD (0.61) | PPARDPPARAPPARGPTGDR2 | |
| SCHEMBL5507055 | 0.82 | PPARD (0.74) | PPARDPPARAPPARG | |
| SCHEMBL5650546 | 0.81 | PPARD (0.60) | PPARDPPARAPPARG | |
| SCHEMBL12800874 | 0.81 | PPARD (0.52) | PPARDPPARAPPARG | |
| SCHEMBL13292305 | 0.81 | PPARD (1.00) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338960-B2 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | claimed |
| EP-2184277-B1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-07-01 | — | — | EP | disclosed |
| US-7338960-B2 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338960-B2 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338960-B2 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1513526-B1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORP (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060089394-A1 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators | SMITHKLINE BEECHAM CORPORATION | 2006-04-27 | — | — | US | disclosed |
| EP-1513526-A1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000315-A1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089394-A1 | Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators | LIPA, PNLIP, CEL | PPARD 83/4885PPARA 11/4885PPARG 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.